Ricerca avanzata

Home > Riviste > Giornale Italiano di Dermatologia e Venereologia > Fascicoli precedenti > Giornale Italiano di Dermatologia e Venereologia 2016 Ottobre;151(5) > Giornale Italiano di Dermatologia e Venereologia 2016 Ottobre;151(5):480-4



Rivista di Dermatologia e Malattie Sessualmente Trasmesse

Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014

Periodicità: Bimestrale

ISSN 0392-0488

Online ISSN 1827-1820


Giornale Italiano di Dermatologia e Venereologia 2016 Ottobre;151(5):480-4


Cyclosporine: a novel therapeutic approach for Burning Mouth Syndrome

Rosita SARACENO 1, Bruno LORÈ 2, Athanasios PAVLIDIS 1, Maria KARAISKOU 3, Claudio ARCURI 4, 5, Sergio CHIMENTI 1, Roberto MAGNATO 2

1 Department of Dermatology, Tor Vergata University of Rome, Rome, Italy; 2 Department of Otolaryngology and Maxillo-Facial Surgery, F. Tappeneir Hospital, Merano, Italy; 3 School of Dentistry, University of Athens, Athens, Greece; 4 Department of Periodontics, Tor Vergata University of Rome, Rome, Italy; 5 Unit of Odontostomatology, S. Giovanni Calibita, Fatebenefratelli Hospital, Rome, Italy

BACKGROUND: The aim of this paper was to evaluate the efficacy and safety of topical cyclosporine applied as mouthwash in the treatment of burning mouth syndrome (BMS).
METHODS: This was a prospective and pilot study conducted by the Department of Dermatology of the University of Rome Tor Vergata. Patients were treated with cyclosporine topically applied as mouthwash for 4 weeks. Clinical improvement was assessed using a 5 grade clinical evaluation scale and a visual analogue scale from 0 to 10 was also used to evaluate the burning symptoms.
RESULTS: Fifteen patients between 22-85 years (61.1±19.3), 11 female and 4 male, with a mean duration of BMS of 12.5 months, completed the study. Five out of 15 patients presented a marked improvement, 6 patients showed a moderate response, 3 patients had a slight improvement and 1 patient did not show any change. The VAS showed a reduction from 8.7 to 3.5. Adverse events were not reported.
CONCLUSIONS: Cyclosporine mouthwash appeared to be safe and beneficial for reducing the burning sensation in patients with BMS representing an alternative therapy in this condition.

lingua: Inglese


inizio pagina